Kestra Medical Technologies, Ltd. Common Stock

Day range

$28.53 – $29.59

Open

$28.95

Prev close

$28.76

Volume

113.44K

Market cap

$1.71B

Shares out

59.56M

P/E

—

P/S

16.05

P/B

7.70

P/FCF

—

ROE

-67.4%

ROA

-43.1%

Debt/Equity

0.33

Div yield

0.03%

As of Oct 23, 2026

• Quarterly earningsSep 14, 2026

  On September 14, 2026, Kestra Medical Technologies, Ltd. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended July 31, 2026.

• Annual meeting resultsSep 10, 2026

  The Kestra Medical Technologies, Ltd. (the "Company") 2026 annual general meeting of shareholders (the "2026 Annual Meeting") was held on September 9, 2026. Voting results for each matter submitted to a vote at the 2026 Annual Meeting are provided below.

• Credit facility drawJul 14, 2026

  The Borrower's net proceeds from the Tranche A Loan were approximately $20.0 million, after deducting estimated debt issuance costs, fees and expenses, and repaying in full the Borrower's obligations under its Prior Loan Agreement with its Prior Lender on July 10, 2026. The remaining proceeds will be used to fund the Company's general corporate and working capital requirements.

• Underwriting agreementDec 4, 2025

  On December 2, 2025, Kestra Medical Technologies, Ltd., a Bermuda exempted company (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein (collectively, the "Underwriters"), related to an underwritten public offering (the "Offering") of 6,900,000 common shares, par value $1.00 per share (the "Common Shares"), at a purchase price per share of $23.00 (the "Offering Price"). The Offering closed on December 4, 2025.

• Preliminary resultsDec 1, 2025

  On December 1, 2025, Kestra Medical Technologies, Ltd. (the "Company") issued a press release announcing certain selected preliminary estimated financial results for the fiscal quarter ended October 31, 2025.

Days to cover

7.3

Short interest

3.28M

Avg volume

449.97K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss, Tops Revenue Estimates
  negativeZacks Investment Research· Sep 14, 2026
• Kestra Names Daniel Finney Vice President of Research & Development
  positiveGlobeNewswire Inc.· Sep 10, 2026
• Phreesia (PHR) Q2 Earnings and Revenues Lag Estimates
  negativeZacks Investment Research· Sep 2, 2026
• Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
  positiveGlobeNewswire Inc.· Aug 26, 2026
• Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
  positiveGlobeNewswire Inc.· Mar 25, 2026